TrialFinder  /  Landscape Report PANIC DISORDER  ·  2026-07-17 Revasser  /  revasserkernel.com
Landscape Report TrialFinder
SOURCE  ClinicalTrials.gov API v2
GENERATED  2026-07-17
VERSION  v1
SAMPLE  100 of 2777 studies

panic disorder

The panic disorder clinical trial landscape includes 2777 actively recruiting trials. Semantic expansion identified 2751 additional trials beyond exact-match search, representing a 10580.8% discovery lift across related conditions and therapeutic approaches.

Recruiting
2777
active trials
Expansion Lift
+10580.8%
2751 additional trials
Top Sponsor
University of Pittsburgh
3 trials
Dominant Phase
NA
64 of 104 sampled
Pipeline Overview
Phase Distribution
NA
64
Early I
2
Phase 1
4
Phase 2
9
Phase 3
6
Phase 4
1
Other
18
Therapeutic Modalities
BEHAVIORAL
58
DEVICE
30
OTHER
29
DRUG
22
DIAGNOSTIC_TEST
4
DIETARY_SUPPLEMENT
4
PROCEDURE
1
Recruiting vs. Completed (2yr)
Recruiting
2777
Completed
2080
Competitive Landscape
Sponsor Classification
85%
7%
7%
OTHER (23)
INDUSTRY (2)
FED (2)
Top Sponsors
SponsorTrialsClass
University of Pittsburgh3OTHER
University of California, San Francisco2OTHER
Medical University of South Carolina2OTHER
University of California, Los Angeles2OTHER
Neurocrine Biosciences2INDUSTRY
Yale University2OTHER
University of Nevada, Reno2OTHER
Virginia Commonwealth University2OTHER
VA Office of Research and Development2FED
University of Alabama at Birmingham2OTHER
Florida State University2OTHER
Texas A&M University1OTHER
Al-Hawash Private University1OTHER
Göteborg University1OTHER
Unity Health Toronto1OTHER
Geographic Distribution
Top U.S. States by Trial Density
StateTrialsTop City
Florida27Miami
California25San Francisco
Texas15San Antonio
Georgia9Decatur
New York9New York
Massachusetts7Boston
Connecticut6New Haven
Ohio6Cleveland
Pennsylvania6Pittsburgh
Utah5Salt Lake City
Virginia5Richmond
Maryland5Baltimore
South Carolina4Charleston
Alabama4Birmingham
Arizona4Phoenix
Missouri4Saint Charles
Nevada4Las Vegas
Oklahoma4Oklahoma City
Tennessee4Nashville
Washington3Bellevue
Expansion Intelligence
+10580.8%
Discovery lift — trials found by semantic expansion that exact-match search misses entirely. This is the gap competitors don't see.
2
Exact
1
Parent
3
Related
3
Comorbid
3
Therapeutic
Top Expansion Terms
  • anxiety disorder Parent
  • agoraphobia Related
  • generalized anxiety disorder Related
  • social anxiety disorder Related
  • depression Comorbid
  • substance use disorder Comorbid
  • cardiovascular anxiety Comorbid
  • SSRI panic Therapeutic
  • exposure therapy panic Therapeutic
  • cognitive behavioral therapy panic Therapeutic

These terms are curated from clinical literature — not generated by a language model. Each captures trials that use variant nomenclature for the same underlying condition or therapeutic area.

Key Findings
What This Landscape Means for panic disorder
high
Standard searches miss 10581% of relevant trials for panic disorder — semantic expansion across related conditions and therapeutic approaches is essential for complete landscape visibility.
2751 additional trials found via expansion vs 26 exact matches
high
6 Phase 3 trials indicate a maturing pipeline with near-term approval potential.
Phase 3 represents 6% of sampled trials
Next Steps
Take Action on This Intelligence
//
Stay Current
Get alerted when new trials open for panic disorder and related conditions. Free tier monitors 1 condition weekly.
Set Up Alerts
[+]
Research Portal
Deploy this intelligence as your organization's permanent research hub — auto-updating, branded, zero hosting cost.
From $497
{<}
API Access
Integrate trial intelligence into your own tools. Full expansion engine, landscape analytics, real-time data.
View Plans
Top Recruiting Trials
20 actively recruiting studies
NCT05959434 PHASE2
Integration of Cognitive Processing Therapy and Relapse Prevention for Alcohol Use Disorder and PTSD
Texas A&M University n=200 Medical University of South Carolina Charleston, South Carolina
Intervention BEHAVIORAL: Cognitive Processing Therapy + Relapse Prevention — Cognitive-Behavioral Therapy that integrates Cognitive Processing Therapy for PTSD with Relapse Prevention for alcohol u...
Eligibility Ages 18 Years
Contact Anka A Vujanovic, Ph.D. · 979-862-6538 · avujanovic@tamu.edu
Bruxism, Anxiety, and Periodontal Status Among Dental Students
Al-Hawash Private University n=100 Al-Hawash Private University, Faculty of Dentistry Homs
Eligibility Ages 18 Years
Contact Ali Abou Sulaiman, Ph.D. in Periodontology · +963956790836 · dr.ali.abousulaiman@hpu.edu.sy
iCBT for Seniors With Depression in Primary Care
Göteborg University n=390 University of Gothenburg Gothenburg
Intervention BEHAVIORAL: iCBT for depression — iCBT depression program with minimal therapist contact offered within 14 days from inclusion and with a duration of 10-1...
Eligibility Ages 65 Years
Contact Dominique Hange, Ass Prof · +46722 245 700 · dominique.hange@allmed.gu.se
Characterizing Dopamine Receptor Binding in Treatment Resistant Depression
Unity Health Toronto n=45 Unity Health Toronto Toronto, Ontario
Intervention DIAGNOSTIC_TEST: PET scans — PET scans and PHNO scans
Eligibility Ages 25 Years – 55 Years
Contact Sakina J Rizvi, PhD · 416-864-6060 · rizvis@smh.ca
NCT06902298 PHASE1, PHASE2
Personalized Ultrasonic Brain Stimulation for Depression (R61)
Brian Mickey n=30 University of Utah Salt Lake City, Utah
Intervention DEVICE: LTFUS to SCC — Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex
Eligibility Ages 18 Years – 65 Years
Contact Brian J Mickey · 801-587-0159 · brian.mickey@utah.deu
COpenhagen Magnetic Personalized Accelerated Brain Circuit Therapy for Treatment Resistant Depression
Danish Research Centre for Magnetic Resonance n=78 Centre of Neuropsychiatric Depression Research Glostrup Municipality
Intervention DEVICE: MagVenture XP Orange Stimulator and active side of MagVenture COOL-B65 coil. — Intermittent theta burst stimulation (iTBS) targeting the left dorsolateral prefrontal cortex (DLPFC) will be administer...
Eligibility Ages 18 Years – 95 Years
Contact Poul Videbech, Professor · +4538640634 · poul.videbech@regionh.dk
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
Sunnybrook Health Sciences Centre n=88 Sunnybrook Health Sciences Centre Toronto, Ontario
Intervention DEVICE: rTMS — Accelerated iTBS treatment
Eligibility Ages 20 Years – 65 Years
Contact Anusha Baskaran, PhD · 416-480-6100 · anusha.baskaran@sunnybrook.ca
NCT06633016 PHASE2
Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
Autobahn Therapeutics, Inc. n=230 Autobahn Site #131 Birmingham, Alabama
Intervention DRUG: ABX-002 — ABX-002 oral solution in 1-mL cyclic olefin polymer prefilled syringes, taken on an empty stomach first thing in the mor...
Eligibility Ages 18 Years – 65 Years
Contact Ashlee Heldreth, MS · 8582573418 · clinicaltrials@autobahntx.com
Functional Near-infrared Spectroscopy for Anxiety Monitoring and Neurofeedback.
National Taiwan University Hospital n=232 National Taiwan University Hospital Taipei
Intervention DEVICE: AI-fNIRS neurofeedback device — The device, with AI-fNIRS signals serving as brain monitor to indicate the level of anxiety, provides mindfulness traini...
Eligibility Ages 18 Years
Contact Yi-Jing Huang, Assistant Professor · +886911164386 · yijinghuang@ntu.edu.tw
NCT05988632 PHASE1, PHASE2
Intranasal Insulin for Treatment of Alcohol Use Disorder
Brown University n=40 Brown University Providence, Rhode Island
Intervention DRUG: Regular Human Insulin then Placebo — Insulin: 80 IU (administered intranasally) THEN Placebo: 0.9% saline solution (administered intranasally)
Eligibility Ages 21 Years
Contact Carolina L Haass-Koffler · 4155191385 · carolina_haass-koffler@brown.edu
Mechanisms of Brain-Heart Injury of Post-Intracranial Hemorrhage
Beijing Tiantan Hospital n=1000 Beijing Tiantan Hospital Affiliated to Capital Medical University Beijing, Beijing Municipality
Intervention DIAGNOSTIC_TEST: Multi-disciplinary assessment — Multi-disciplinary assessment including blood tests, CSF test, electrocardiograms, ultrasound, imaging, etc
Eligibility Ages 18 Years – 80 Years
Internet-Delivered Cognitive Behaviour Therapy for PTSD Among Public Safety Personnel
University of Regina n=300 Department of Psychology and Collaborative Centre for Justice and Safety Regina, Saskatchewan
Intervention BEHAVIORAL: PSP PTSD Course — A tailored ICBT intervention designed to treat symptoms of PTSD will be delivered to public safety personnel. Clients wi...
Eligibility Ages 18 Years
Contact Heather D Hadjistavropoulos, PhD · 306-585-5133 · heather.hadjistavropoulos@uregina.ca
NCT07412756 PHASE3
A Study of Brenipatide in Adult Participants With Major Depressive Disorder
Eli Lilly and Company n=1000 Accellacare - Moorpark Moorpark, California
Intervention DRUG: Brenipatide — Administered SC
Eligibility Ages 18 Years – 75 Years
Contact Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or · 1-317-615-4559 · LillyTrials@Lilly.com
NCT06248710 PHASE2, PHASE3
Dog Presence and Oxytocin on Trust Towards Therapists
Dr. Karin Hediger n=176 University of Basel Basel, Canton of Basel-City
Intervention DRUG: Oxytocin nasal spray — Syntocinon nose spray is usually applied in the context of labour and breast feeding. In this study, however, it will be...
Eligibility Ages 18 Years
Contact Karin Hediger, Prof. Dr. · +41 (0)61 207 65 80 · elena.pauli@unibas.ch
NCT06793488 EARLY_PHASE1
Anxiety During Abstinence in AUD
Columbia University n=60 Columbia University Irving Medical Center New York, New York
Intervention DRUG: Disulfiram 250 mg — Disulfiram will be used in Participants with Alcohol Use Disorder only to facilitate abstinence.
Eligibility Ages 21 Years – 55 Years
Contact A B Srivastava, MD · 646-774-8189 · abs2257@cumc.columbia.edu
Effectiveness of an Online Biopsychosocial Intervention to Improve Well-being and Mental Health During Pregnancy
University Rovira i Virgili n=228 Centre d'Atenció Primària Sant Pere Reus, Tarragona
Intervention OTHER: Biopsychosocial Cognitive Behavioral Intervention — The study intervention is based on a biopsychosocial approach (considers the interaction between: biological factors suc...
Eligibility Ages 18 Years, FEMALE only
Contact Carmen Hernández Martínez, Doctor · +34675245881 · carmen.hernandez@urv.cat
Translation and Validation of the Limbs, Pain, Autonomy, Depression, Anxiety and Quality of Life Scales in Albanian
Universidad Católica San Antonio de Murcia n=300 Jasemin Todri Murcia, Murcia
Eligibility Ages 18 Years – 80 Years
Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons
University of Wisconsin, Madison n=96 University of Wisconsin Madison, Wisconsin
Intervention BEHAVIORAL: Acceptance and Commitment Therapy (ACT) — ACT: Therapy that builds in traditional cognitive behavioral therapy principles but emphasizes different processes in be...
Eligibility Ages 18 Years
Contact Madilyn Michels · 920-602-5612 · mgmichels@wisc.edu
Natural History of Depression, Bipolar Disorder and Suicide Risk
National Institute of Mental Health (NIMH) n=500 National Institutes of Health Clinical Center Bethesda, Maryland
Eligibility Ages 18 Years – 120 Years
Contact Kelly T Hurst, Ph.D. · (877) 646-3644 · moodresearch@mail.nih.gov
Real-World NeuroModulate: Investigating Non-Invasive Brain Stimulation for Neuropsychiatric Disorders at TUM
Technical University of Munich n=100 University Hospital Technical University of Munich München
Intervention OTHER: iTBS Treatment — 20 iTBS sessions over 4 weeks, lDLPFC (BeamF3), 600Pulses.
Eligibility Ages 18 Years